Jaguar Health Earnings Call Transcripts
Fiscal Year 2026
-
Secured major non-dilutive funding through a licensing deal, fueling late-stage clinical programs for rare diseases MVID and SBS-IF. Proof of concept data show significant reductions in parenteral support, with pivotal trials and regulatory filings underway.
-
A major licensing deal with FuturePak provides significant non-dilutive funding and shifts commercial focus to R&D and rare disease programs. Clinical trials for MVID and SBS show promising results, supporting accelerated regulatory pathways and potential blockbuster opportunities.
Fiscal Year 2025
-
Q4 2025 net revenue rose 5% sequentially but fell 8% year-over-year, with a strategic shift to rare disease focus and a transformative out-license deal securing $16M upfront. Clinical milestones for crofelemer in intestinal failure are expected in the next 6-12 months.
-
FDA renewed conditional approval for Canalevia-CA1 in dogs, with a $250,000 grant supporting pivotal trials for full approval. Expansion into Europe and broader indications is underway, with significant market potential and key catalysts expected through 2025.
-
Q3 2025 revenue rose 4% sequentially to $3.1M, with clinical and regulatory progress in key crofelemer programs for rare diseases and cancer therapy-related diarrhea. Business development efforts target non-dilutive funding and partnerships.
-
Recent catalysts include FDA meetings, orphan drug applications, and new clinical data for crofelemer in cancer and rare diseases. Statistically significant results in breast cancer and groundbreaking reductions in parenteral support for rare diseases are driving business development and partnership opportunities.
-
Recent catalysts include orphan drug designation filings and a grant for animal health trials, supporting expansion into cancer and rare disease indications. Regulatory progress and de-risked programs are driving new partnership and funding opportunities.
-
Transformative clinical and regulatory catalysts are driving late-stage development of crofelemer for rare and cancer therapy-related indications, with significant progress in MVID and breast cancer. Business development and licensing negotiations are underway to support growth.
-
New clinical data show crofelemer reduces parenteral nutrition needs in ultra-rare MVID patients, with regulatory discussions underway for expedited approval. Multiple late-stage trials and business development efforts target significant orphan and cancer markets.
-
Q2 2025 revenue grew 35% sequentially and 10% year-over-year, driven by clinical and regulatory catalysts. Losses increased, but key programs in rare diseases and cancer therapy-related diarrhea advanced, with business development and licensing deals targeted for non-dilutive funding.
-
Recent FDA meetings have set a clear path for neurofilament biomarker analysis in ALS, with pivotal data collection and submission planned for Q3–Q4 and a regulatory decision expected in early 2026. A confirmatory phase III trial will launch late 2024, focusing on survival.
-
Q1 2025 saw a 6% year-over-year revenue decline and higher losses, but Mytesi prescription volume grew, and rare disease programs delivered promising results. Multiple regulatory and business catalysts are expected in 2025–2026, with a focus on non-dilutive funding.
-
Initial proof-of-concept results show crofelemer significantly reduces TPN needs in pediatric MVID and SBS patients, supporting its potential as a transformative therapy for intestinal failure. Ongoing global trials and regulatory strategies target expedited approval and broad market access.
-
Multiple clinical and regulatory catalysts are expected soon, including proof-of-concept data for rare pediatric diseases and a key FDA meeting for MyTESY in breast cancer. Strategic partnerships, global regulatory designations, and recent bridge financing position the company for near-term milestones.
-
Multiple clinical and regulatory catalysts are expected this year, including proof-of-concept data for rare diseases and a potential FDA pathway for cancer therapy-related diarrhea. Strong advocacy and business development opportunities are converging, making this a pivotal year.
-
Crofelemer's commercial and pipeline progress includes expanding into cancer supportive care, with a supplemental NDA for cancer therapy-related diarrhea and new rare disease trials underway. Strategic partnerships and Medicare changes are expected to drive growth in 2025.
Fiscal Year 2024
-
2024 net revenue grew 20% year-over-year to $11.7 million, with Q4 revenue up 53% year-over-year. Key catalysts in rare disease and cancer supportive care programs are expected in 2025, supported by recent bridge financing and ongoing clinical trials.
-
The company highlighted robust financial growth, a strong patent portfolio, and a pipeline led by crofelemer, with recent clinical focus on cancer therapy-related diarrhea and rare diseases. Key catalysts include new product launches, upcoming clinical trial results, and regulatory milestones.
-
Q3 2024 net revenue rose 14% sequentially and 11% year-over-year, with Mytesi prescription volume up and the launch of Gelclair for oral mucositis. OnTarget trial data in breast cancer will be presented at a major symposium, and multiple late-stage clinical and commercial catalysts are expected in the coming months.
-
Significant clinical progress was announced, with crofelemer showing statistical significance in breast cancer patients for cancer therapy-related diarrhea and a new product, GelClair, launching for oral mucositis. Multiple rare disease trials and a robust early-stage pipeline support future growth.
-
Key updates include robust revenue growth for Mytesi, progress in cancer and rare disease clinical programs, and a focus on cancer supportive care with new product launches. Strategic partnerships and early-stage pipeline developments are set to drive near-term catalysts.
-
Q2 2024 revenue grew 16% sequentially and 2% year-over-year, with operational losses narrowing. Key clinical progress was made in cancer and rare disease indications for crofelemer, and the October 2024 launch of Gelclair is set to expand the supportive care portfolio.
-
The OnTarget trial for crofelemer did not meet its primary endpoint across all tumor types but showed clinically relevant benefits in breast and lung cancer subgroups. Further analysis and regulatory discussions are planned, with a focus on patient-centered supportive care.